Neogen Corporation's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the first quarter 2026 to a ratio of 6.41, above the company average. This is a clear sign of healthy business climate in the In Vitro & In Vivo Diagnostic Substances industry and improving liquidity at their respective customers, during the first quarter 2026. Average receivable collection period, for the Neogen in Aug 31 2026 quarter, has decreased to 57 days, compared to 58 days, in the May 31 2026 quarter.

If we take a look into Healthcare sector 399 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Aug 31 2026 from 2271 to 2755.

What is Receivable Turnover Ratio?
What is Neogen Corporation Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

NEOG Receivables Turnover Ratio	(Aug 31 2026) I. Quarter	(May 31 2026) IV. Quarter	(Feb 28 2026) III. Quarter	(Nov 30 2025) II. Quarter	(Aug 31 2025) I. Quarter
Y / Y Receivable Change	-1.63 %	-4.29 %	-14.35 %	-19.55 %	-17.41 %
Y / Y Revenue Change	6.67 %	-0.58 %	-4.21 %	-2.45 %	-3.67 %
Receivable Turnover Ratio (TTM)	6.41	6.28	6.21	6.03	5.76
NEOG's Total Ranking	# 2755	# 2271	# 2116	# 2468	# 2592
Accounts Receivable average collection period days	57	58	59	60	63
Seq. Receivable Change	-7.22 %	7.08 %	3.86 %	-4.66 %	-9.73 %
Seq. Revenue Change	-1.17 %	6.89 %	-6.09 %	7.52 %	-7.88 %

Receivable Turnover Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 9
Healthcare Sector	# 400
Overall Market	# 2755

Receivable Turnover Ratio Statistics
High	Average	Low
0.78	0.57	0.2
(May 31 2014)		(Aug 31 2024)

NEOG Company Profile • Back to NEOG Efficiency Comparisons • Compare NEOG Receivables Turnover Ratio to its Competitors

Financial Statements
Neogen's Accounts Receivable	$ 136 Millions	Visit NEOG's Balance sheet
Neogen's Sales TTM	$ 884 Millions	Visit NEOG's Income Statement
Sources of NEOG's Revenues		Visit NEOG's Sales by Geography

Other Accounts Receivable Turnover Ratios
In Vitro & In Vivo Diagnostic Substances Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
NEOG's Receivable Turnover Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
NEOG's Growth Rates	NEOG's Roa	NEOG's Inventory Turnover Ratio	NEOG's Dividend Comparisons
NEOG's Profitability Ratios	NEOG's Roi	NEOG's Asset Turnover Ratio	NEOG's Dividend Growth
NEOG's Valuation Ratios	NEOG's Roe	NEOG's Financial Strength Ratios	NEOG's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Aug 31 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Aug 31 2026	Receivable at quarter ending Aug 31 2026
Biogen Inc	15.19	$ 10,297.300 Millions	$ 677.900 Millions
Lifestance Health Group Inc	14.89	$ 1,676.889 Millions	$ 112.631 Millions
Corcept Therapeutics Inc	13.44	$ 963.647 Millions	$ 71.710 Millions
Chemed Corporation	12.65	$ 2,661.041 Millions	$ 210.387 Millions
Caredx Inc	11.75	$ 497.396 Millions	$ 42.330 Millions
Teladoc Health Inc	11.50	$ 2,468.143 Millions	$ 214.604 Millions
Biodesix Inc	11.45	$ 105.212 Millions	$ 9.192 Millions
Icu Medical Inc	11.32	$ 2,183.556 Millions	$ 192.845 Millions
Mannkind Corporation	10.97	$ 413.370 Millions	$ 37.686 Millions
Iqvia Holdings Inc	10.43	$ 17,311.000 Millions	$ 1,659.500 Millions
Voyager Therapeutics Inc	9.84	$ 25.108 Millions	$ 2.551 Millions
Encompass Health Corporation	9.41	$ 6,338.100 Millions	$ 673.625 Millions
Bausch Health Companies Inc	9.15	$ 11,113.000 Millions	$ 1,215.000 Millions
Pacs Group Inc	8.88	$ 5,705.049 Millions	$ 642.729 Millions
Lexicon Pharmaceuticals Inc	8.77	$ 38.537 Millions	$ 4.396 Millions
Axogen inc	8.71	$ 266.926 Millions	$ 30.654 Millions
Avita Medical Inc	8.65	$ 84.683 Millions	$ 9.795 Millions
Ensign Group Inc	8.62	$ 5,674.305 Millions	$ 658.477 Millions
Pediatrix Medical Group Inc	8.57	$ 1,959.124 Millions	$ 228.471 Millions
Tenet Healthcare Corp	8.54	$ 22,154.000 Millions	$ 2,593.250 Millions
Brightspring Health Services Inc	8.50	$ 9,479.144 Millions	$ 1,114.763 Millions
Sotera Health Company	8.49	$ 1,230.250 Millions	$ 144.974 Millions
Acadia Pharmaceuticals Inc	8.46	$ 1,202.301 Millions	$ 142.117 Millions
Novavax inc	8.33	$ 411.649 Millions	$ 49.414 Millions
Tactile Systems Technology Inc	8.23	$ 357.176 Millions	$ 43.385 Millions
Penumbra Inc	8.22	$ 1,560.334 Millions	$ 189.735 Millions
Inspire Medical Systems inc	8.15	$ 882.194 Millions	$ 108.207 Millions
Adapthealth Corp	8.14	$ 3,152.043 Millions	$ 387.280 Millions
Rhythm Pharmaceuticals Inc	8.03	$ 280.748 Millions	$ 34.950 Millions
Alphatec Holdings Inc	7.91	$ 839.652 Millions	$ 106.153 Millions

Date modified: 2026-10-08T04:22:54+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.